What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Factor IX Complex Concentrate market?

Key drivers include rising prevalence of hemophilia B and advances in treatment options.

What challenges does the Factor IX Complex Concentrate market face?

Challenges include high costs, limited access to treatment in developing regions, and regulatory hurdles.

Which regions are the leaders in the Factor IX Complex Concentrate market?

North America and Europe are the leading regions, due to high adoption rates and strong healthcare infrastructure.

Who are the top companies in the Factor IX Complex Concentrate market?

Top companies include Pfizer, Bayer, and Sanofi, which offer a range of treatment options.

What future opportunities exist in the Factor IX Complex Concentrate market?

Future opportunities include emerging markets, gene therapy, and innovative delivery systems.

How will technology impact the future outlook of the Factor IX Complex Concentrate market?

Technology will play a key role in developing more effective treatments and improving patient outcomes.

What is the current regulatory landscape for the Factor IX Complex Concentrate market?

The regulatory landscape is stringent, with strict guidelines for approval and monitoring of treatments.

How will the Factor IX Complex Concentrate market size evolve in the next 5 years?

The market size is expected to increase significantly, driven by growing demand and advances in treatment options.

Factor IX Complex Concentrate Expansion Opportunities & Forecast Analysis 2033

Factor IX Complex Concentrate by Application (Hemophilia B, Acquired Coagulation Factor Deficiency), by Types (Beriplex, Profilnine, Octaplex, Prothromplex, Cofact, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $1052 million

CAGR: 12%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $1052 million

CAGR: 12%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Factor IX Complex Concentrate Market Size | CAGR 12% Forecast 2033

Factor IX Complex Concentrate Expansion Opportunities & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $1052 million

CAGR: 12%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $1052 million

CAGR: 12%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Factor IX Complex Concentrate Market Overview

The Factor IX Complex Concentrate market refers to the industry involved in the production and distribution of Factor IX complex concentrates, which are used to treat bleeding disorders such as hemophilia B and other factor IX deficiencies. As the Factor IX Complex Concentrate market size is expected to grow significantly, driven by an increasing prevalence of bleeding disorders and advancements in treatment options, it is essential to understand the growth outlook, market forecast, and industry expansion. The scope of this market encompasses various types of factor IX complex concentrates, including recombinant and plasma-derived products, and their applications in different end-use settings, such as hospitals, clinics, and home care.

Loading chart…

The current Factor IX Complex Concentrate market size is approximately $1.3 billion. The market is expected to grow at a CAGR of around 6-7% during the forecast period from 2026 to 2033, driven by macro drivers such as increasing demand for bleeding disorder treatments and advancements in recombinant technology. Key forces shaping the industry include technology shifts, such as the development of novel recombinant factor IX products, regulatory requirements, and competitive intensity among market players. The largest region in the Factor IX Complex Concentrate market is North America, while the fastest-growing region is expected to be the Asia-Pacific region, driven by increasing awareness and adoption of advanced treatments for bleeding disorders. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends and developments to make strategic decisions and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	1.05 billion
Revenue forecast in 2033	1.83 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CSL Behring; Grifols; Octapharma; Takeda; Prothya Biosolutions
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Factor IX Complex Concentrate market is poised for significant growth, driven by increasing demand for effective treatments of bleeding disorders. The market dynamics are shaped by various factors, including technological advancements, regulatory frameworks, and shifting consumer preferences.

Growth Drivers2 items

Advances in recombinant DNA technology have enabled the development of more effective and safer Factor IX Complex Concentrate products, driving the growth forecast of the market.

Increasing awareness and diagnosis of bleeding disorders, such as hemophilia B, have led to a rise in demand for Factor IX Complex Concentrate, contributing to the expansion of the Factor IX Complex Concentrate market size.

Restraints2 items

Stringent regulatory requirements and high development costs associated with Factor IX Complex Concentrate products may hinder the entry of new players into the market, limiting competition and innovation.

The high cost of Factor IX Complex Concentrate treatments can be a significant barrier to access, particularly in developing countries, which may constrain the growth forecast of the market.

Opportunities2 items

Emerging markets, such as Asia Pacific and Latin America, offer significant opportunities for growth due to their large and growing populations, increasing awareness of bleeding disorders, and improving healthcare infrastructure.

The development of novel Factor IX Complex Concentrate products with improved efficacy and safety profiles can help companies to differentiate themselves and gain a competitive edge in the Factor IX Complex Concentrate market.

Challenges2 items

The Factor IX Complex Concentrate market is highly competitive, with several established players, which can make it challenging for new entrants to gain traction and market share.

Fluctuations in the global economy and trade policies can impact the supply chain and pricing of Factor IX Complex Concentrate products, affecting the Factor IX Complex Concentrate market size and growth.

Market Segmentation

Loading chart…

The Application segment of the Factor IX Complex Concentrate market is a critical aspect of Factor IX Complex Concentrate segmentation, as it directly influences the overall market size. This segment is defined by the various uses of Factor IX Complex Concentrate, such as in the treatment of bleeding disorders, including hemophilia B and other factor IX deficiencies. The application segment is further divided into subtypes, including [object Object] and [object Object], which contribute to the overall market size by catering to different patient needs and preferences.

The Types segment of the Factor IX Complex Concentrate market refers to the different forms and subtypes of Factor IX Complex Concentrate available, such as plasma-derived and recombinant products. This segment is essential in understanding the market taxonomy of Factor IX Complex Concentrate, as it highlights the various product offerings and their respective market shares. The types segment is also divided into subtypes, including [object Object] and [object Object], which play a crucial role in determining the overall market size and growth prospects.

Factor IX Complex Concentrate Segmentation Breakdown10 items

Application

Hemophilia B

Acquired Coagulation Factor Deficiency

Types

Beriplex

Profilnine

Octaplex

Prothromplex

Cofact

Other

Regional Insights

Loading chart…

The Factor IX Complex Concentrate market growth is anticipated to be driven by various regional factors. North America is the largest region, accounting for approximately 40% of the market, driven by high adoption rates, favorable policies, and significant investments in healthcare infrastructure. Key drivers in North America include increasing demographics of the aging population, a mature ecosystem, and a high level of infrastructure development.

The fastest-growing region is expected to be Asia Pacific, driven by rising demographics, increasing adoption of advanced healthcare technologies, and significant investments in infrastructure development. Europe is also expected to contribute significantly to the Factor IX Complex Concentrate market growth, driven by favorable policies, high ecosystem maturity, and a large patient population. Latin America and Middle East & Africa are expected to experience steady growth, driven by increasing adoption rates and improving infrastructure.

Key Drivers by Region5 items

North America: high adoption rates, favorable policies, significant investments

Europe: favorable policies, high ecosystem maturity, large patient population

Asia Pacific: rising demographics, increasing adoption of advanced healthcare technologies, significant investments in infrastructure development

Latin America: increasing adoption rates, improving infrastructure

Middle East & Africa: increasing adoption rates, improving infrastructure

Competitive Landscape

The Factor IX Complex Concentrate market is moderately consolidated, with a mix of global players and local companies competing for market share. The Factor IX Complex Concentrate competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on expanding their product portfolios and strengthening their distribution networks, while local companies are leveraging their regional presence and cost advantages to compete.

Companies in the Factor IX Complex Concentrate market are adopting various strategies to differentiate themselves and gain a competitive edge. Common strategies include M&A, partnerships, product launches, expansion, R&D, and localization. However, companies face challenges such as margin pressure, compliance costs, and commoditization, which can erode their profitability. To overcome these challenges, companies are focusing on developing innovative products, strengthening their service models, and building strong channel partnerships.

CSL Behring: regional expansion

Grifols: vertical integration

Octapharma: premium pricing

Takeda: OEM tie-ups

Prothya Biosolutions: innovation pipeline

Other companies: local manufacturing

Key Factor IX Complex Concentrate Companies5 items

CSL Behring

Grifols

Octapharma

Takeda

Prothya Biosolutions

Market Ecosystem

The Factor IX Complex Concentrate ecosystem spans the entire value chain, from upstream technology providers and raw material suppliers to midstream manufacturers and downstream distributors, and ultimately to end users. This ecosystem is characterized by a complex interplay of participants, each contributing to the creation and capture of value. The ecosystem boundaries are defined by the flow of materials, technologies, and services, which are transformed at each stage to create the final product.

Raw material suppliers — providing key components

OEMs/manufacturers — producing Factor IX Complex Concentrate

Technology providers — developing manufacturing technologies

Distributors/channel partners — delivering products to end users

End users/buyers — healthcare institutions and patients

Regulators/standards bodies — overseeing safety and efficacy

Service providers/after-sales — offering support and maintenance

In the Factor IX Complex Concentrate ecosystem, control points are primarily held by regulators and standards bodies, who influence adoption through approvals and guidelines. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact manufacturing processes. Switching costs and partnerships are also critical, as companies may need to invest in new technologies or form alliances to ensure interoperability. As the ecosystem differs by region, with varying regulatory requirements and market conditions, a thorough value chain analysis is necessary to navigate these complexities.

Recent Industry Insights

The Factor IX Complex Concentrate industry trends have witnessed significant developments over the last 12-18 months, driven by strategic partnerships, mergers and acquisitions, and innovative product launches. Recent partnerships have focused on enhancing manufacturing capabilities and expanding distribution networks, while mergers and acquisitions have led to market consolidation and increased competition. Furthermore, regulatory changes have prompted companies to adapt their product development strategies, ensuring compliance with evolving standards.

Notably, there has been a shift in consumer trends, with a growing demand for more effective and convenient treatment options. In response, companies have invested in funding rounds and expansions to support research and development of novel Factor IX Complex Concentrate products. As the industry continues to evolve, it is likely that we will see more emphasis on innovative technologies and collaborative efforts to address the complex needs of patients with bleeding disorders, ultimately shaping the future of the Factor IX Complex Concentrate industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Factor IX Complex Concentrate market outlook. The market attractiveness is moderate, driven by the increasing prevalence of bleeding disorders and the growing demand for effective treatments. The competitive intensity is high, with several key players operating in the market. The long-term outlook is positive, with opportunities for growth and innovation in the development of new products and technologies.

The innovation landscape is evolving, with a focus on improving the efficacy and safety of Factor IX Complex Concentrate products. The demand-supply balance is stable, with manufacturers working to meet the growing demand for these products. However, key risk factors include regulatory challenges, supply chain disruptions, and intense competition. Overall, the Factor IX Complex Concentrate market is expected to experience steady growth, driven by the increasing demand for effective treatments for bleeding disorders.

11 items

1. Executive Summary

2. Factor IX Complex Concentrate Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Factor IX Complex Concentrate Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Factor IX Complex Concentrate Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hemophilia B

6.1.2. Acquired Coagulation Factor Deficiency

6.2. Global Factor IX Complex Concentrate Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Beriplex

6.2.2. Profilnine

6.2.3. Octaplex

6.2.4. Prothromplex

6.2.5. Cofact

6.2.6. Other

6.3. Global Factor IX Complex Concentrate Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Factor IX Complex Concentrate Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Factor IX Complex Concentrate Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Factor IX Complex Concentrate Market Competition by Key Manufacturers

8.1. Global Factor IX Complex Concentrate Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Factor IX Complex Concentrate: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. CSL Behring

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Grifols

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Octapharma

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Takeda

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Prothya Biosolutions

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Factor IX Complex Concentrate Market

Figure 4: Global Factor IX Complex Concentrate Market: Drivers

Figure 5: Global Factor IX Complex Concentrate Market: Challenges

Figure 6: Global Factor IX Complex Concentrate Market: Trends

Figure 7: Global Factor IX Complex Concentrate Market: Opportunity

Figure 8: Global Factor IX Complex Concentrate Market: Restraint

Figure 9: Global Factor IX Complex Concentrate Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Factor IX Complex Concentrate Market Value (USD Million) By Region

Figure 15: Global Factor IX Complex Concentrate Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Factor IX Complex Concentrate Market Value (USD Million) By Region

Figure 23: Global Factor IX Complex Concentrate Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Factor IX Complex Concentrate Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Factor IX Complex Concentrate Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Factor IX Complex Concentrate Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Factor IX Complex Concentrate Market Value (USD Million) By Region

Table 10: Global Factor IX Complex Concentrate Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Factor IX Complex Concentrate Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Factor IX Complex Concentrate Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Factor IX Complex Concentrate Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: CSL Behring Basic Information And Sales Area

Table 31: CSL Behring. Products Portfolio

Table 32: Grifols Basic Information And Sales Area

Table 33: Grifols. Products Portfolio

Table 34: Octapharma Basic Information And Sales Area

Table 35: Octapharma. Products Portfolio

Table 36: Takeda Basic Information And Sales Area

Table 37: Takeda. Products Portfolio

Table 38: Prothya Biosolutions Basic Information And Sales Area

Table 39: Prothya Biosolutions. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Factor IX Complex Concentrate Market Value (USD Million) By Region

Table 45: Global Factor IX Complex Concentrate Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Factor IX Complex Concentrate Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.05 billion
Revenue forecast in 2033	1.83 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CSL Behring; Grifols; Octapharma; Takeda; Prothya Biosolutions
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options